1-3 of 3
Julia Driessen
Close
Sort by
Journal Articles

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Julia Driessen, Wouter J. Plattel, Lydia Visser, Anke Van Den Berg, Josée M. Zijlstra, Sanne Tonino, Gerben JC Zwezerijnen, Ronald Boellaard, Marie José Kersten, Arjan Diepstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 9213–9215.
https://doi.org/10.1182/blood-2022-166120
Published: 2022
Journal Articles

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten
Journal: Blood
Blood (2021) 138 (Supplement 1): 879.
https://doi.org/10.1182/blood-2021-147810
Published: 2021
Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4049.
https://doi.org/10.1182/blood-2019-125495
Published: 2019